BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 1716335)

  • 1. Circulating hemopoietic progenitors mobilized by cancer chemotherapy and by rhGM-CSF in the treatment of high-grade non-Hodgkin's lymphoma.
    Bregni M; Siena S; Magni M; Bonadonna G; Gianni AM
    Leukemia; 1991; 5 Suppl 1():123-7. PubMed ID: 1716335
    [No Abstract]   [Full Text] [Related]  

  • 2. Autografting with peripheral blood stem cells mobilized by sequential interleukin-3/granulocyte-macrophage colony-stimulating factor following high-dose chemotherapy in non-Hodgkin's lymphoma.
    Haas R; Ehrhardt R; Witt B; Goldschmidt H; Hohaus S; Pförsich M; Ehrlich H; Färber L; Hunstein W
    Bone Marrow Transplant; 1993 Dec; 12(6):643-9. PubMed ID: 7511017
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heterogeneity of circulating hematopoietic progenitors in cancer patients treated with high-dose cyclophosphamide and recombinant human granulocyte macrophage colony stimulating factor (rhGM-CSF).
    Siena S; Bregni M; Ravagnani F; Brando B; Tarella C; Bonadonna G; Gianni AM
    Haematologica; 1990; 75 Suppl 1():6-10. PubMed ID: 2190884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful autografting following myeloablative conditioning therapy with blood stem cells mobilized by chemotherapy plus rhG-CSF.
    Hohaus S; Goldschmidt H; Ehrhardt R; Haas R
    Exp Hematol; 1993 Apr; 21(4):508-14. PubMed ID: 7681782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sequential studies on the role of mitoxantrone, high-dose cytarabine, and recombinant human granulocyte-macrophage colony-stimulating factor in the treatment of refractory non-Hodgkin's lymphoma.
    Ho AD; Del Valle F; Haas R; Engelhard M; Hiddemann W; Rückle H; Schlimok G; Thiel E; Andreesen R; Fiedler W
    Semin Oncol; 1990 Dec; 17(6 Suppl 10):14-8; discussion 18-9. PubMed ID: 2259918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) subsequent to chemotherapy improves collection of blood stem cells for autografting in patients not eligible for bone marrow harvest.
    Haas R; Hohaus S; Egerer G; Ehrhardt R; Witt B; Hunstein W
    Bone Marrow Transplant; 1992 Jun; 9(6):459-65. PubMed ID: 1352717
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapid and sustained allogeneic transplantation using immunoselected CD34(+)-selected peripheral blood progenitor cells mobilized by recombinant granulocyte- and granulocyte-macrophage colony-stimulating factors.
    Corringham RE; Ho AD
    Blood; 1995 Sep; 86(5):2052-4. PubMed ID: 7544651
    [No Abstract]   [Full Text] [Related]  

  • 8. Combination chemotherapy with mitoguazon, ifosfamide, MTX, etoposide (MIME) and G-CSF can efficiently mobilize PBPC in patients with Hodgkin's and non-Hodgkin's lymphoma.
    Aurlien E; Holte H; Pharo A; Kvaløy S; Jakobsen E; Smeland EB; Kvalheim G
    Bone Marrow Transplant; 1998 May; 21(9):873-8. PubMed ID: 9613778
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation of colony-forming cells, long-term culture initiating cells and CD34+ cells in apheresis products from patients mobilized for peripheral blood progenitors with different regimens.
    Bender JG; Lum L; Unverzagt KL; Lee W; Van Epps D; George S; Coon J; Ghalie R; McLeod B; Kaizer H
    Bone Marrow Transplant; 1994 Apr; 13(4):479-85. PubMed ID: 7517260
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD34+ dose-driven administration of granulocyte colony-stimulating factor after high-dose chemotherapy in lymphoma patients.
    Todisco E; Castagna L; Sarina B; Mazza R; Magagnoli M; Balzarotti M; Nozza A; Siracusano L; Timofeeva I; Anastasia A; Demarco M; Santoro A
    Eur J Haematol; 2007 Feb; 78(2):111-6. PubMed ID: 17313558
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of granulocyte-macrophage colony-stimulating factor (GM-CSF) in combination with hydroxyurea as post-transplant therapy in chronic myelogenous leukemia patients autografted with unmanipulated hematopoietic cells.
    Carlo-Stella C; Regazzi E; Andrizzi C; Savoldo B; Garau D; Montefusco E; Vignetti M; Mandelli F; Rizzoli V; Meloni G
    Haematologica; 1997; 82(3):291-6. PubMed ID: 9234574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of chemotherapy and GM-CSF on hemopoietic progenitor cell mobilization in multiple myeloma.
    Tarella C; Boccadoro M; Omedé P; Bondesan P; Caracciolo D; Frieri R; Bregni M; Siena S; Gianni AM; Pileri A
    Bone Marrow Transplant; 1993 Apr; 11(4):271-7. PubMed ID: 7683551
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Filgrastim post-chemotherapy mobilizes more CD34+ cells with a different antigenic profile compared with use during steady-state hematopoiesis.
    Möhle R; Pförsich M; Fruehauf S; Witt B; Krämer A; Haas R
    Bone Marrow Transplant; 1994 Nov; 14(5):827-32. PubMed ID: 7534163
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ex vivo expansion of megakaryocyte progenitors: effect of various growth factor combinations on CD34+ progenitor cells from bone marrow and G-CSF-mobilized peripheral blood.
    Gehling UM; Ryder JW; Hogan CJ; Hami L; McNiece I; Franklin W; Williams S; Helm K; King J; Shpall EJ
    Exp Hematol; 1997 Oct; 25(11):1125-39. PubMed ID: 9328449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term cultures to evaluate engraftment potential of CD34+ cells from peripheral blood after mobilization by chemotherapy with and without GM-CSF.
    Benboubker L; Domenech J; Linassier C; Desbois I; Delain M; Lamagnere JP; Colombat P; Binet C
    Exp Hematol; 1995 Dec; 23(14):1568-73. PubMed ID: 8542948
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of prior therapy on the in vitro proliferative potential of stem cell factor plus filgrastim-mobilized CD34-positive progenitor cells.
    Shapiro F; Yao TJ; Moskowitz C; Reich L; Wuest DL; Heimfeld S; McNiece IK; Gabrilove J; Nimer S; Moore MA
    Clin Cancer Res; 1997 Sep; 3(9):1571-8. PubMed ID: 9815845
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) after chemotherapy in patients with non-Hodgkin's lymphoma; a placebo-controlled double blind phase III trial.
    Kaku K; Takahashi M; Moriyama Y; Nakahata T; Masaoka T; Yoshida Y; Shibata A; Kaneko T; Miwa S
    Leuk Lymphoma; 1993 Oct; 11(3-4):229-38. PubMed ID: 8260897
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of peripheral blood CD34+ progenitor cells mobilized with chemotherapy and granulocyte colony-stimulating factor.
    Teofili L; Iovino MS; Sica S; Pierelli L; Menichella G; De Stefano V; Rumi C; Leone G
    Exp Hematol; 1994 Sep; 22(10):990-5. PubMed ID: 7522187
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In leukapheresis products from non-Hodgkin's lymphoma patients, the immature hematopoietic progenitors show higher CD90 and CD34 antigenic expression.
    Villaron EM; Almeida J; Lopez-Holgado N; Sanchez-Guijo FM; Alberca M; Blanco B; Sanchez-Abarca LI; Lopez O; Perez-Simon JA; San Miguel JF; del Cañizo MC
    Transfus Apher Sci; 2007 Oct; 37(2):145-56. PubMed ID: 17983836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Primitive hematopoietic progenitor cells are present in peripheral blood autografts.
    Tong J; Gianni AM; Siena S; Srour EF; Bregni M; Hoffman R
    Blood Cells; 1994; 20(2-3):351-62; discussion 362-3. PubMed ID: 7538339
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.